- While the Removing Barriers to Colorectal Cancer Screening Act of 2019, H.R. 1570, is still seeking more cosponsors, the Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020, H.R. 2339, passed the House of Representative on February 28th. In addition to stricter regulations on tobacco products and e-cigarettes, this language includes similar language to waive Medicare coinsurance for colorectal cancer screening tests, otherwise known as the "polyp penalty".
- A letter was sent from Democratic leads to the Center for Medicaid and Medicare Services (CMS) Administrator regarding the proposed discontinuation of advanced premium tax credits (APTC). Read the letter here.
The comprehensive spending package for Fiscal Year (FY) 2020 includes the following health policy and program reauthorizations.
- Reauthorization of the Patient Centered Outcomes Research Institute (PCORI) for 10 years.
- A nationwide increase in the age for the sale of tobacco products to 21 years
- Increases generic drug competition to lower the price of drugs
- Repeal of the Affordable Care Act’s (ACA) Medical Device Tax, Health Insurance Tax, and Cadillac Tax
- Rare Disease Legislative Advocates (RDLA) visited the nation’s capital the week of February 24th yo educate legislators about the need to support research, improve patient care, and awareness about rare diseases.
- Vice President Pence is to lead the coordination of the US response to the coronavirus. Pence has appointed Debbie Birx, an ambassador-at-large for the State Department who currently focuses on HIV and AIDS, to serve as the "White House Coronavirus Response Coordinator" responsible for leading the administration's strategy on fighting the outbreak. Birx and three new members of the White House's coronavirus task force - Treasury Secretary Steven Mnuchin, Surgeon General Jerome Adams and National Economic Council Director Larry Kudlow - will report to Pence and Health and Human Services Secretary Alex Azar.
- The House Committee of Ways and Means voiced unanimous, bipartisan support of the Consumer Protections Against Suprise Medical Bills Act of 2020 (H.R. 5826). This legislation has thirty-eight cosponsors and was introduced by Representative Richard Neal, Chairman of the Ways and Means Committee. Find the press release here.
- On February 11th, the House Committee on Education and Labor advanced the Ban Surprise Billing Act (H.R. 5800), which was introduced on February 7, 2020. This legislation is intended to build on solutions to protect patients from surprise medical bills. Find the press release here.
- During the State of the Union Address on February 6th, President Trump remarked that his major priorities include; lowering the cost of healthcare and prescription drugs, and protecting patients with preexisting conditions. Find President Trump's entire remarks here.
- On January 30, 2020, the Centers for Medicare & Medicaid Services (CMS) issued guidance allowing states to apply for capped block grants through Medicaid demonstration waivers, particularly in order to cover services for the Medicaid expansion population (i.e., adults under the age of 65). The guidance also allows states that receive such block grants to make other changes to their programs (e.g., formularies for prescription drugs). Two resolutions in the House of Representatives were created. H. Res. 826 created on February 3rd, expressed the opinion that the House of Representatives feels CMS should withdraw this guidance. On February 5th the House then created H. Res. 833, officially disapproving of the guidance permitting block grants under Medicaid demonstration waivers. Both resolutions were passed on February 6th, the Senate is not expected to act on a similar resolution.
- The Supreme Court declined a motion to fast-track a challenge to the Affordable Care Act (ACA). This is in response to a lower court ruling declaring the individual mandate of the ACA unconstitutional. Further action by the lower court or the Supreme Court is not likely in the near future. Read the Docket information here.
- Legislation addressing drug pricing and surprise medical billing appears to be stalled at this time. The ongoing tension between the House Energy & Commerce Committee and the House Ways & Means Committee has stifled progress on surprise medical billing. The House-passed drug pricing legislation, H.R. 3, is pending in the Senate, a bipartisan proposal (S.2543), is having difficulty finding traction. Proponents of addressing these key topics are hoping that progress can be made between now and May, when Congress must act on several expiring health authorities.
- The Agency for Healthcare Research and Quality (AHRQ) is seeking nominations for individuals qualified to serve as members of the U.S. Preventive Services Task Force (USPSTF), an independent body of experts in prevention and evidence-based medicine that works to improve the health of all Americans by making evidence-based recommendations about the effectiveness of clinical preventive services and health promotion. The deadline to submit a nomination is March 15th.
- The Patient-Centered Outcomes Research Institute (PCORI), fresh from a 10-year reauthorization, announced the appointment of Dr. Nakela Cook as its new executive director on January, 15th. Most recently, Dr. Cook served as chief of staff at the National Heart, Lung, and Blood Institute at NIH. Read the announcement here.
- Senate Finance Committee Chairman Charles Grassley (R-IA) continues to push for action on his drug pricing legislation, the Prescription Drug Pricing Reduction Act of 2019 (S.2543). Grassley has made appeals to both Senate Majority Leader McConnell, and House Speaker Pelosi to proceed with his bipartisan plan. Grassley’s Senate bill is less comprehensive than the House-passed bill, the Elijah E. Cummings Lower Drug Costs Now Act (H.R.3), but does have support on both sides of the aisle.
- Progress on surprise medical billing legislation continues to be stalled because of a dispute between House committees. Follow the link to find more information on the End Surprise Billing Act of 2019 (H.R.861).